FDA guidance

Asenapine Maleate (Tablet - Sublingual)

FDA guidance · Draft · issued Nov 28, 2018

Key facts

Title Asenapine Maleate (Tablet - Sublingual)
Status Draft
Issue date Nov 28, 2018
Center Center for Drug Evaluation and Research
Regulated product Drugs
Topics Product-Specific Guidance

At a glance

  • None Product codes referenced
  • None Recognized standards referenced

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About FDA guidance documents

FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.

Source: U.S. Food and Drug Administration (FDA), Guidance Documents

Browse all FDA guidance documents